Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.

Steven Lipkin,John Lee,David Imagawa,Stephen M Hewitt,Chris Tucker,Jason A Zell,Vanessa Wong,Angela Garcia,Rachel Gonzalez,Gary Della Zanna,Ellen Richmond,L M Rodriguez,M Bigg,F Schnoll-Sussmans,Frank Meyskens

CANCER PREVENTION RESEARCH（2011）

引用 5|浏览10

暂无评分

摘要

Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8).

查看译文

关键词

drug safety,immunohistochemistry,drug efficacy,high performance liquid chromatography,phase 2 clinical trial,tandem mass spectrometry

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要